If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

Share Price is delayed by 15 minutes
Get Live Data
175.50    -1.50 (-0.85%)
Bid:
174.00
Ask:
177.00
Spread: 3.00 (1.724%)
Market Cap: £3.25m
NBB Live PriceLast checked at - London Stock Exchange

Intraday Norman Broadb Share Chart

Trading Update

24 Jan 2023 07:00

RNS Number : 5985N
Norman Broadbent PLC
24 January 2023
 

Norman Broadbent plc

("Norman Broadbent", "NBB" or the "Group")

Trading Update

Norman Broadbent (AIM: NBB), a leading London quoted Executive Search and Interim Management firm offering a diversified portfolio of integrated Leadership Acquisition & Advisory Services, provides the following unaudited trading update for the three months ended 31 December 2022 ("Q4 2022") and the year ended 31 December 2022 ("FY22").

Q4 2022 Highlights

· Group Net Fee Income ("NFI") up 29% to £2.34m (Q4 2021: £1.81m)

· NFI up 40% compared to the average for the previous 3 quarters of £1.67m

· Edinburgh office established ahead of plan to bolster position in Scotland

· Sub-let over capacity in London office with income entirely offsetting cost in 2023 of newly opened Aberdeen and Edinburgh offices

 

FY22 Highlights

· NFI up 27% to £7.34m (FY 2021: £5.8m)

· Positive EBITDA expected to be approximately £100k, up c.£400k on FY 2021's LBITDA of £303k

· Highest expected annual NFI and EBITDA figures since FY 2019 and Company very much back to pre-pandemic levels

· Very positive run rate carry over from Q4 2022 into Q1 2023 with forward contracted revenue up 27% to £1.28m (Q1 2022: £1.01m)

Kevin Davidson, Group CEO of Norman Broadbent, commented:

"I am delighted with our Q4 2022 performance and the achievements of the team in 2022 as a whole. As planned, the Company generated positive annual EBITDA whilst also growing headcount significantly, thus building the platform for continued profitable growth in future years. This includes a number of fee generating hires made in Q4 2022 who will begin delivering revenue in Q1 2023. The quality and seniority of mandates has also been consistently rising over 2022 with the average fee per engagement increasing by 50% over that period. 

There has been significant change across the business over the past 18 months which has been driven and embraced by the entire team. We have very high levels of engagement and collective ambition for the future of Norman Broadbent.

We are aiming to deliver annual EBITDA of £1.25 million in 2025 through organic growth whilst continuing to seek acquisition opportunities. While the economic headwinds remain challenging, I am confident that the necessary foundations are in place to enable us to achieve this target."

For further information please contact:

Norman Broadbent plc

Kevin Davidson, CEO

Mehr Malik, CFO

 

+44 (0) 20 7484 0000

 

Shore Capital (Nominated Adviser and Broker)

Tom Griffiths / Tom Knibbs (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 (0)20 7408 4090

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFERLFIVFIV
Date   Source Headline
12th Nov 20212:30 pmRNSDirector/PDMR Shareholding
1st Nov 20217:00 amRNSAppointment of Group Managing Director
27th Sep 20217:02 amRNSSubscription Results and PDMR Dealing
27th Sep 20217:00 amRNSInterim Results for Six Months Ended 30 June 2021
12th Aug 20217:00 amRNSBoard Changes
12th Jul 20217:00 amRNSBoard Changes
25th Jun 202112:30 pmRNSResult of AGM
15th Jun 20217:00 amRNSAppointment of Executive Chairman
24th May 20217:00 amRNSFinal Results and Annual Accounts
13th May 202111:59 amRNSHolding(s) in Company
12th May 202112:17 pmRNSHolding(s) in Company
12th May 20219:39 amRNSHolding(s) in Company
19th Apr 202111:59 amRNSNotice of Results
19th Apr 202111:53 amRNSHolding(s) in Company
25th Jan 20217:00 amRNSFY2020 Trading Update
26th Nov 20207:00 amRNSFunding Update
23rd Nov 20204:54 pmRNSHolding(s) in Company
21st Oct 20201:45 pmRNSAppointments - Group Managing Director & Others
16th Oct 20201:00 pmRNSDirector/PDMR Shareholding & Concert Party Update
5th Oct 20203:01 pmRNSIssue of Equity
5th Oct 20207:00 amRNSAcquisition of minority interest in NBIMv
28th Sep 20207:00 amRNSInterim Results
27th Aug 202010:40 amRNSDirectorate Change
24th Aug 202010:59 amRNSDirector/PDMR Shareholding
28th Jul 202010:18 amRNSResult of AGM and Appointment of Chair
28th Jul 20207:00 amRNSAGM Statement and Trading Update
16th Jul 202010:35 amRNSHolding(s) in Company
29th Jun 20207:00 amRNSFinal Results and Annual Accounts
26th May 202011:32 amRNSDirector/PDMR Shareholding
18th May 202012:33 pmRNSDirector/PDMR Shareholding
18th May 20207:00 amRNSTrading Update
11th Mar 202012:00 pmRNSAppointment of CFO & COO
9th Mar 20207:00 amRNSChange of address
3rd Mar 20207:00 amRNSExpansion driven by increased client demand
28th Feb 20207:00 amRNSUpdate: Chief Financial Officer Succession
24th Jan 20207:00 amRNSTrading Update
10th Dec 20197:00 amRNSNorman Broadbent Group partners with UN Women UK
26th Sep 20197:00 amRNSInterim Results for six months ended 30 June 2019
9th Sep 20197:00 amRNSNew and Enhanced Working Capital Facility
23rd Aug 201911:31 amRNSHolding(s) in Company
23rd Aug 201910:51 amRNSShareholder Update and Director/PDMR Shareholding
6th Aug 20194:17 pmRNSDirector/PDMR Shareholding
22nd Jul 201912:46 pmRNSResult of AGM
22nd Jul 20197:00 amRNSAGM Statement - Norman Broadbent returns to profit
28th Jun 20197:00 amRNSFinal Results and Annual Accounts
10th Jun 201910:32 amRNSCEO recognised by CEO Today magazine
27th Mar 20193:29 pmRNSHolding(s) in Company
13th Feb 20197:00 amRNSTrading Update
28th Sep 20187:00 amRNSInterim Results
6th Jun 201811:49 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.